Samvardhana Motherson slips 2%; 3 reasons why brokerages have cut target price are…

Samvardhana Motherson share price is down 2% intra-day today. This decline comes after several brokerages downgraded their target price for the automotive component giant. As the stock remains below its 52-week high of Rs 3,270.95, with a market capitalisation of Rs 3.37 lakh crore, let’s take a look at what is the brokerages say on Samvardhana Motherson stock:

Nuvama: Maintains Buy, target price reduced to Rs 166

According to the brokerage firm Nuvama, Samvardhana Motherson EBITDA in Q3FY25 earnings was in line with expectations. Although the company reported a slightly lower than expected revenue of Rs 27,670 crore, the company managed to keep its earnings in line due to better margins in its wiring harness and integrated assemblies segments.

As per the brokerage firm, the company’s revenue grew 8% YoY, majorly driven by its inorganic initiatives, which contributed Rs 22.4 billion. Furthermore, the brokerage is also optimistic about the company’s long term growth, with a projected 6% revenue CAGR for FY25-27. The report also noted the company’s management and efforts to increase its content per vehicle and tab into new markets though inorganic opportunities.

ALSO READNuvama has Buy recommendation on these 3 stocks today 

Although a muted outlook for North America and Europe for FY26E, the brokerage has revised its earnings estimates slightly downward, cutting FY25E–FY27E EPS by 4-7%. However, the firm is still constructive on SAMIL’s prospects, with a ‘BUY’ rating and a revised target price of Rs 166, down from Rs 194 previously.

“We are constructive on SAMIL’s prospects on the back of strong
management capability, inorganic initiatives, pending order book and increasing content; reiterate ‘BUY’, with an SotP TP of INR166 (earlier INR194), implying a blended PE of 23x (26x earlier),” added the brokerage in its report.

Motilal Oswal: Maintains Buy, target price reduced to Rs 160

As per the brokerage, the company’s Q3FY25 operational performance is in line with estimates. Furthermore, it has lowered its FY26E EPS by 15%, it has largely maintained its FY25E EPS, noting that the company’s long-term prospects remain intact.

The brokerage believes that the company’s Q3 performance highlights SAMIL’s business resilience. The brokerage has reiterated its ‘BUY’ rating, with a revised target price of Rs 160, based on a valuation of 24x Dec’26E EPS.

“We expect MOTHERSO to continue to outperform global automobile sales,

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth